Compare ResMed Inc. (RMD) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Global X SuperDividend ETF — how do they compare? ResMed Inc. trades at $223.62 (market cap $31.92B), while Global X SuperDividend ETF trades at $24.56. The key difference: ResMed Inc. pays a 1.2% dividend while Global X SuperDividend ETF pays none, and Global X SuperDividend ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| RMD | SDIV | |
|---|---|---|
Market Cap | $31.92B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $293.73 | $26.34 |
52-Week Low | $182.82 | $22.90 |
Enterprise Value | $31.28B | — |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $211.94, down 5.06% on the day, following a Q4 2026 earnings beat but weaker fiscal 2027 revenue guidance. The stock shows strong fundamentals with a 26.94% net income margin and consistent earnings beats, while technical indicators are neutral with support at $204 and resistance at $218. Recent news highlights growth in sleep device demand but concerns over sales forecasts.
Outlook remains mixed: robust profitability and a $235 consensus price target suggest upside, but near-term pressure from guidance and technical neutrality poses risks. Investors should weigh solid financial health against market sentiment shifts.
SDIV trades at $24.81, up 1.02% with a neutral technical signal. The ETF maintains a consistent dividend payout of $0.18 monthly, providing a high yield for income-focused investors. Recent news highlights SDIV's role in diversification away from AI-heavy portfolios, with Seeking Alpha upgrading it to a buy rating citing attractive valuation and 9.29% yield. Technical indicators show mixed signals with bearish moving averages but neutral oscillators.
SDIV offers exposure to global high-dividend stocks with minimal tech exposure, appealing during market volatility. Key risks include concentration in financials and energy sectors, interest rate sensitivity, and geopolitical factors affecting dividend sustainability. The fund's 6% yield target provides income stability but requires monitoring of underlying holdings' financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
